UBP-310

UBP-310 is a small-molecule, willardiine-derived competitive antagonist of kainate-type ionotropic glutamate receptors. Developed in academic research at the University of Bristol, it is primarily used as a pharmacological research tool to study the physiological roles of kainate receptors. UBP-310 exhibits high potency and selectivity for the GluK1 (formerly GluR5) subunit of the kainate receptor, with lower affinity for GluK3 and minimal activity at GluK2 subunits. It has been investigated in preclinical models for its potential to reduce neuronal network hyperexcitability in conditions such as epilepsy (including focal cortical dysplasia and temporal lobe epilepsy) and chronic pain, though it is not currently being developed for clinical use.

Other names

(S)-1-(2-amino-2-carboxyethyl)-3-(2-carboxy-thiophene-3-yl-methyl)-5-methylpyrimidine-2,4-dione(S)-1-(2-amino-2-carboxyethyl)-3-(2-carboxythiophene-3-yl-methyl)-5-methylpyrimidine-2,4-dione(αS)-α-amino-3-[(2-carboxy-3-thienyl)methyl]-3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinepropanoic acidUBP 310UBP310UBP-310